Streetbeat News

Analyst Ratings

ACIU

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on AC Immune (NASDAQ:ACIU) and maintained a price target of $16. This reaffirmation of the company's stock rating and price target suggests continued confidence in AC Immune's prospects.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:55 pm

ITOS

JP Morgan analyst Daniel Wolle has maintained an Overweight rating on ITeos Therapeutics (NASDAQ:ITOS) but reduced the price target from $32 to $29.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:55 pm

IQV

JP Morgan analyst Anne Samuel has maintained an Overweight rating on IQVIA Holdings (IQV) but has reduced the price target from $262 to $239.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:53 pm

INAB

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on IN8bio (NASDAQ:INAB) and maintained a $14 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:52 pm

BAP

JP Morgan analyst Domingos Falavina maintains a Neutral rating on Credicorp (NYSE:BAP) and reduces the price target from $175 to $162.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:51 pm

AVGR

HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on Avinger (NASDAQ:AVGR) and increased the price target from $1.6 to $5.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:48 pm

JELD

JP Morgan analyst Michael Rehaut has maintained a Neutral rating on JELD-WEN Holding (NYSE:JELD) and increased the price target from $17.5 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:48 pm

ASH

Stifel analyst Vincent Anderson has maintained a Buy rating on Ashland (NYSE:ASH) but reduced the price target from $110 to $96, as reported on November 10, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:46 pm

JANX

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $35 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:44 pm

XRAY

Stifel analyst Jonathan Block has maintained a Hold rating on Dentsply Sirona (NASDAQ:XRAY) and reduced the price target from $35 to $32.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:44 pm